Drug treatment for hypertension
40 results
1 - 40
Spironolactone most effective add-on for patients with resistant hypertension (PATHWAY-2)- New US guidelines suggest risk-based approach to stage 1 hypertension
- Greater blood pressure lowering with a “quadpill” (quarter doses of 4 drugs) than with standard-dose monotherapy (QUARTET)
- Some benefit to treating mild hypertension to prevent stroke, CV deaths, and overall mortality
- One-third of people eligible for weight loss drugs are not represented in clinical research
- BP lowering by any means is beneficial in most
- 24-hour ambulatory blood pressure readings: more informative for the risks of all-cause and cardiovascular mortality
- Catheter ablation marginally better than usual care for symptomatic atrial fibrillation (CABANA)
- Good reasons not to lower the definition of high blood pressure in adults
- In patients with prior stroke and hypertension, lower BP target no more effective in preventing recurrent strokes (RESPECT)
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Lorcaserin is safe, but only modestly effective (6 pounds greater weight loss than placebo)
- Lowering blood pressure does not decrease the risk of T2DM in persons with hypertension; ACEIs/ARBs do
- Tight control no different from less-tight control of hypertension in pregnancy
- Intravenous remdesivir for 3 days reduces hospitalization in outpatients with symptomatic COVID-19
- Endovascular denervation lowers blood pressure (RADIANCE-HTN SOLO)
- In hypertensive CKD, intensive BP control only helpful for higher risk patients
- Vitamins C and E ineffective for PIH
- Vericiguat for heart failure reduces hospitalization, but not mortality
- Liraglutide produces modest weight loss and lots of side effects at a high cost
- Normotensive patients at intermediate risk of CV disease do not benefit from ARB + HCTZ (HOPE-3)
- Intensive cardiovascular screening has little benefit in older men (DANCAVAS)
- Pimavanserin of uncertain benefit to treat psychosis in patients with dementia
- Antihypertensive therapy beneficial for patients with BP < 140/90 and history of CVD
- High-dose barium enemas prevent recurrent diverticular bleeding
- Cefepime/taniborbactam is superior to meropenem for microbiologic, but not clinical, cures of complicated UTI (CERTAIN-1 study)
- Similar risk of major malformations in infants of asthmatic women with alternate treatment regimens
- Sulodexide given long-term may reduce recurrent VTE in patients with initial unprovoked VTE
- IV iron improves symptoms in chronic heart failure patients with iron deficiency
- 17-OHPC may not reduce recurrent preterm birth or decrease neonatal morbidity
- New oral analogue to remdesivir is similarly effective to nirmatrelvir-ritonavir for mild to moderate symptomatic COVID-19
- Sibutramine increases risk of CV events and is not effective for weight loss
- Glyburide not beneficial for women with mild gestational diabetes
- Controlled-release combo of phentermine and topiramate decreases weight (CONQUER)
- Patent foramen ovale closure in cryptogenic stroke reduces recurrence rate compared with antiplatelet agents
- British Society for Rheumatology Guideline for managing patients with gout